TerminatedPhase 1

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Stopped: Study closed due to portfolio prioritization

United States133 participantsStarted 2020-05-29

Plain-language summary

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Monotherapy Inclusion Criteria (Parts A and B) * Histologically- or cytologically-confirmed advanced or metastatic malignancy, defined as: * One of the following tumor types: * Unresectable locally-advanced or metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal (GE) junction carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma (HNSCC), bladder cancer, cervical cancer, ovarian cancer, or triple negative breast cancer (TNBC) * Lymphomas, including: * cHL * Diffuse large B-cell lymphoma (DLBCL) * Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) * Lymphoma: Participants should have disease progression on or after treatment with standard therapies expected to provide benefit in the judgement of the investigator. * cHL: Participants must have received at least 3 prior systemic therapies. Participants should have had disease recurrence or progression following brentuximab vedotin therapy or have been ineligible to receive brentuximab vedotin. Participants who have not received autologous stem cell transplant (SCT) must have refused or been deemed ineligible. Participants should have received or not be eligible to have received an anti-PD-1 agent. * DLBCL: Participants must have received at least 2 prior systemic chemo-immunotherapy regimens, including an anti-CD20 agent and combination chemotherapy. Unless clinically contraindicated, participants should have had disease that has relaps…

What they're measuring

Number of participants with adverse events (AEs)

Timeframe: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years

Number of participants with laboratory abnormalities by grade

Timeframe: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years

Number of participants with a dose-limiting toxicity (DLT) at each dose level

Timeframe: Up to 21 days

Trial details

NCT IDNCT04254107

SponsorSeagen Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-12-01

View on ClinicalTrials.gov More Non-small Cell Lung Cancer trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of participants with adverse events (AEs)

Timeframe: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years

Number of participants with laboratory abnormalities by grade

Timeframe: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years

Number of participants with a dose-limiting toxicity (DLT) at each dose level

Timeframe: Up to 21 days